首页> 外文期刊>BJOG: an international journal of obstetrics and gynaecology >Medical management of late intrauterine death using a combination of mifepristone and misoprostol.
【24h】

Medical management of late intrauterine death using a combination of mifepristone and misoprostol.

机译:米非司酮和米索前列醇联合用于宫内晚期死亡的医学管理。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: To assess the efficacy and safety of mifepristone in combination with misoprostol in the management of late fetal death. DESIGN: Observational study. SETTING: Aberdeen Maternity Hospital, Aberdeen. METHODS: A consecutive series of 96 women with intrauterine death after 24 weeks of gestation were studied. Each woman received a single dose of 200 mg mifepristone orally, following which a 24-48 hour interval was recommended before administration of misoprostol. For gestations of 24-34 weeks, 200 microg of intravaginal misoprostol was administered, followed by four oral doses of 200 microg at three hourly intervals. Gestations over 34 weeks were given a similar regimen but a reduced dose of 100 microg misoprostol. RESULTS: The average induction to delivery interval was 8.5 hours. Ninety-five women (98.9%) were delivered within 72 hours of administration of first dose of misoprostol, with 66.7%, 87.5%, 92.7% and 95.8% women delivering within 12, 24, 36 and 48 hours, respectively. No significant correlation was found between mean induction to delivery interval and maternal age, parity, Bishop's score, birthweight and mifepristone/ misoprostol interval. The induction to delivery interval was shorter with increasing gestation (P = 0.04). Mild side effects were noted in eight (8.3%) women. Three (3.1%) women had treatment for presumed or proven pelvic sepsis. No cases of uterine tachysystole, haemorrhage or coagulopathy were recorded. CONCLUSION: The combination of mifepristone and misoprostol for induction of labour following late fetal death is an effective and safe regimen. The induction to delivery interval with this regimen appears shorter than studies using mifepristone or misoprostol.
机译:目的:评估米非司酮联合米索前列醇治疗晚期胎儿死亡的有效性和安全性。设计:观察性研究。地点:香港仔阿伯丁妇产医院。方法:对连续妊娠96周后宫内死亡的96例妇女进行了系列研究。每位妇女口服200 mg米非司酮单次服用,之后建议间隔24-48小时再服用米索前列醇。对于24-34周的妊娠,给予200微克的阴道内米索前列醇,然后每三个小时间隔四次口服200微克的口服剂量。超过34周的妊娠也接受了类似的治疗方案,但剂量降低了100微克米索前列醇。结果:平均诱导分娩间隔为8.5小时。 95名妇女(98​​.9%)在首次服用米索前列醇72小时内分娩,其中66.7%,87.5%,92.7%和95.8%的妇女分别在12、24、36和48小时内分娩。在平均分娩诱导时间与产妇年龄,胎次,Bishop评分,出生体重和米非司酮/米索前列醇间隔之间没有显着相关性。随着妊娠的增加,对分娩间隔的诱导时间较短(P = 0.04)。在八名(8.3%)妇女中发现了轻度的副作用。三名(3.1%)妇女接受了假定的或证实的骨盆败血症的治疗。没有记录到子宫收缩,出血或凝血病的病例。结论:米非司酮和米索前列醇联合用于晚期胎儿死亡后引产是一种安全有效的方案。与使用米非司酮或米索前列醇的研究相比,该方案诱导的分娩间隔似乎更短。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号